.png){kind=small}
As a specialised CRO for dermatological therapeutics, we go beyond traditional study execution, delivering biomarker-driven clinical evaluation through validated assays, condition-specific expertise, and rigorous, reproducible methodologies.
From what to why
Clinical testing
vs biological understanding
In dermatology, demonstrating safety and efficacy is essential, but often limited by how studies are designed and measured.
Many studies rely on broad clinical endpoints or insufficient biomarker depth, making it difficult to:
Without a robust study design, validated assays, and appropriate candidate selection, even strong formulations risk producing incomplete or inconclusive data.
From what to why
Clinical evaluation grounded in biology
Sequential provides biomarker-driven clinical evaluation for dermatological therapeutics, combining human biomarker profiling, microbiome sequencing, and validated clinical endpoints.
By connecting clinical outcomes with underlying biological pathways, we ensure data is biologically meaningful, reproducible, and generated under SOP-controlled conditions.
Leveraging extensive internal datasets and condition-specific validated assays, we deliver high-quality, physiologically relevant data suitable for clinical development and regulatory use.
Deep experience across key dermatological indications, including acne, atopic dermatitis, rosacea, and ageing-related skin changes.
Condition-specific expertise
Validated assays & panels
SOP-backed, physiologically relevant assays designed for reproducibility, biological meaning, and regulatory alignment.
Specialised recruitment
Structured participant screening and standardized, non-invasive collection methods to ensure data integrity and scalable study execution.
A rigorous,
end-to-end
clinical framework
.png)
2
Specialized Recruitment
We can recruit ethnically diverse participants globally using GDPR-compliant, IRB-approved protocols to deliver timely, meaningful results for targeted populations. Our studies are conducted across three clinical testing facilities in New York, Cambridge (UK), and Singapore.
.png)
Sequential Patch
4
Biomarker Discovery
In our laboratory, samples undergo stringent processing to generate high-quality data using multi-omics technologies. We capture host and microbial responses from skin sites.
6
Biomarker Packages
We design specialised biomarker packages informed by in-depth skin science, delivering relevant, quantifiable data to support therapeutic validation and product development.
1
Study Protocols & Design
We collaborate with clients to develop study protocols tailored to their objectives and endpoints
.png)
Recruitment
3
Non-Invasive Collection
We ensure standardised, non-invasive sampling with clinically validated systems, delivering reproducible, globally consistent, and statistically robust data.
